Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
NCT ID: NCT03202472
Last Updated: 2020-07-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2017-08-03
2019-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy
NCT02432118
Radiofrequency of Breast Cancers in Non Surgical Patients
NCT00210223
Radiofrequency Ablation in Breast Cancer
NCT02281812
Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement
NCT00548392
Percutaneous Removal and Margin Ablation for Breast Cancer
NCT00574301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Evaluate the feasibility of utilizing a new Federal Drug Administration (FDA)-cleared radiofrequency tag for localization of non-palpable breast lesions and provide preliminary data for a larger study.
OUTLINE:
Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
After completion of study, patients are followed up within 2 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (radiofrequency-guided localization)
Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
Implanted Medical Device
Radiofrequency tag
Mammography
Undergo mammogram for image-guided placement of radiofrequency tag
Questionnaire Administration
Ancillary studies
Radiofrequency (RFID) -Guided Localization
Undergo radiofrequency-guided localization
Ultrasonography
Undergo ultrasound for image-guided placement of radiofrequency tag
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Implanted Medical Device
Radiofrequency tag
Mammography
Undergo mammogram for image-guided placement of radiofrequency tag
Questionnaire Administration
Ancillary studies
Radiofrequency (RFID) -Guided Localization
Undergo radiofrequency-guided localization
Ultrasonography
Undergo ultrasound for image-guided placement of radiofrequency tag
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read and write English
* Patients with breast lesions that are non-palpable that require surgical removal
* Lesions and/or clip targetable with image guidance
Exclusion Criteria
* Stage IV breast cancer
* Pregnant or lactating females
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maggie DiNome, MD
Role: PRINCIPAL_INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
DiNome ML, Kusske AM, Attai DJ, Fischer CP, Hoyt AC. Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery. Breast Cancer Res Treat. 2019 May;175(1):165-170. doi: 10.1007/s10549-019-05143-w. Epub 2019 Jan 28.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2017-01097
Identifier Type: REGISTRY
Identifier Source: secondary_id
UCLA LOCalizer 00 I
Identifier Type: -
Identifier Source: secondary_id
17-000668
Identifier Type: OTHER
Identifier Source: secondary_id
17-000668
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.